Vir Biotechnology Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
367
- Stock Symbol
-
VIR
- Investments
-
4
- Share Price
-
$8.39
- (As of Friday Closing)
Vir Biotechnology General Information
Description
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Contact Information
Website
www.vir.bioCorporate Office
- 1800 Owens Street
- Suite 900
- San Francisco, CA 94158
- United States
Corporate Office
- 1800 Owens Street
- Suite 900
- San Francisco, CA 94158
- United States
Vir Biotechnology Stock Performance
As of 20-Nov-2026, Vir Biotechnology’s stock price is $8.39. Its current market cap is $1.56B with 186M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.39 | $8.87 | $5.45 - $14.38 | $1.56B | 186M | 2.44M | -$1.19 |
Vir Biotechnology Financials Summary
As of 30-Sep-2026, Vir Biotechnology has a trailing 12-month revenue of $302M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,452,382 | 432,586 | 209,205 | (215,593) |
| Revenue | 302,454 | 66,520 | 63,712 | 39,494 |
| EBITDA | (206,720) | (466,328) | (580,355) | (695,733) |
| Net Income | (184,790) | (437,987) | (521,960) | (615,061) |
| Total Assets | 1,111,855 | 1,002,823 | 1,398,813 | 1,919,060 |
| Total Debt | 90,775 | 97,852 | 97,891 | 124,540 |
Vir Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vir Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Vir Biotechnology Comparisons
Industry
Financing
Details
Vir Biotechnology Competitors (81)
One of Vir Biotechnology’s 81 competitors is Rigel Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Precigen | Formerly VC-backed | Germantown, MD | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Vir Biotechnology Patents
Vir Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213138-A1 | Pharmaceutical formulations for antibody delivery | Pending | 01-Apr-2025 | ||
| WO-2026207501-A1 | Therapeutic uses of egfr targeted bispecific polypeptides | Pending | 28-Mar-2025 | ||
| WO-2026198954-A1 | Methods and compositions for the treatment and prevention of marburg virus infection | Pending | 21-Mar-2025 | ||
| WO-2026156215-A1 | Combination therapy for treating hepatitis d virus (hdv) infection | Pending | 17-Jan-2025 | ||
| WO-2026136923-A1 | Therapeutic uses of her-2 targeted bispecific polypeptides | Pending | 20-Dec-2024 | C07K16/32 |
Vir Biotechnology Signals
Vir Biotechnology Investments & Acquisitions (4)
Vir Biotechnology’s most recent deal was a Merger/Acquisition with Agenovir. The deal was made on 09-May-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Agenovir | 09-May-2018 | Merger/Acquisition | Biotechnology | ||
| Humabs BioMed | 25-Sep-2017 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| TomegaVax | 01-Jan-2017 | Later Stage VC | Drug Discovery | ||
| TomegaVax | 01-Jan-2016 | Merger/Acquisition | Drug Discovery |
Vir Biotechnology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.86 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vir Biotechnology Exits (2)
Vir Biotechnology’s most recent exit was on 01-Jan-2017 from TomegaVax. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| TomegaVax | 01-Jan-2017 | Completed |
|
||
| TomegaVax | 01-Jan-2016 | Merger/Acquisition | Completed |
Vir Biotechnology FAQs
-
When was Vir Biotechnology founded?
Vir Biotechnology was founded in 2016.
-
Where is Vir Biotechnology headquartered?
Vir Biotechnology is headquartered in San Francisco, CA.
-
What is the size of Vir Biotechnology?
Vir Biotechnology has 367 total employees.
-
What industry is Vir Biotechnology in?
Vir Biotechnology’s primary industry is Drug Discovery.
-
Is Vir Biotechnology a private or public company?
Vir Biotechnology is a Public company.
-
What is Vir Biotechnology’s stock symbol?
The ticker symbol for Vir Biotechnology is VIR.
-
What is the current stock price of Vir Biotechnology?
As of 20-Nov-2026 the stock price of Vir Biotechnology is $8.39.
-
What is the current market cap of Vir Biotechnology?
The current market capitalization of Vir Biotechnology is $1.56B.
-
What is Vir Biotechnology’s current revenue?
The trailing twelve month revenue for Vir Biotechnology is $302M.
-
Who are Vir Biotechnology’s competitors?
Rigel Pharmaceuticals, Adaptimmune Therapeutics, Precigen, Adimab, and Sorrento Therapeutics are some of the 81 competitors of Vir Biotechnology.
-
What is Vir Biotechnology’s annual earnings per share (EPS)?
Vir Biotechnology’s EPS for 12 months was -$1.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process